MedTrace Logo

Evaluation of the Impact of Reduced Immunosuppression

NCT05238155 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2026-03-23

No results posted yet for this study

Summary

Graft-versus-host disease (GVHD) is a life-threatening complication of transplantation. It occurs when the donor graft contains immunologically competent T-cells that recognize the recipient as foreign.

Conditions

  • Graft Vs Host Disease

Interventions

DRUG

antimetabolite

When OLT recipients are discharged following transplantation, they are typically prescribed a triple immunosuppression maintenance regimen, consisting of a calcineurin inhibitor, an antimetabolite, and a corticosteroid. Over the last several years, there have been changes made to this protocol, and the current protocol now suggests

Sponsors & Collaborators

  • Methodist Health System

    lead OTHER

Principal Investigators

  • Jessica Crotty, PharmD · Methodist Health System

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-19
Primary Completion
2025-07-29
Completion
2025-07-29

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05238155 on ClinicalTrials.gov